{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:12:35Z","timestamp":1793398355169,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>To compare the efficacy and safety of different interventions [including antimuscarinics, mirabegron, OnabotulinumtoxinA, sacral neuromodulation (SNM) and peripheral tibial nerve stimulation (PTNS)] for treating idiopathic overactive bladder (OAB). PubMed, Embase, Cochrane Library, and other sources were searched for randomized controlled trials (RCTs) comparing interventions for overactive bladder from 1 January 2000 to 19 April 2021. A systematic review and network meta-analysis were performed by two authors independently. Fifty-five RCTs involving 32,507 patients were included in this analysis. Overall, antimuscarinics, mirabegron, OnabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation were more efficacious than placebo, and sacral neuromodulation showed the best effect for reducing micturition frequency, urgency episodes and urgency urinary incontinence episodes. OnabotulinumtoxinA was the best intervention for achieving reductions of 100 and \u226550% in the number of urinary incontinence episodes\/day, and peripheral tibial nerve stimulation was the best intervention for reducing urinary incontinence episodes. Antimuscarinics, mirabegron and peripheral tibial nerve stimulation had a similar efficacy for reducing micturition frequency, urinary incontinence episodes and urgency urinary incontinence episodes. The results revealed that all interventions examined herein were efficacious for managing adult overactive bladder syndrome compared with placebo. Furthermore, sacral neuromodulation and OnabotulinumtoxinA were the most efficient treatments for overactive bladder.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=251966<\/jats:ext-link>\n                      ], identifier [CRD42021251966].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.1014291","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:53:26Z","timestamp":1666248806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Peng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment.","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU guideline amendment 2019.","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries.","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/nau.24957","article-title":"Short-term effect of magnetic stimulation added to bladder training in women with idiopathic overactive bladder: a prospective randomized controlled trial.","volume":"41","author":"Tezer","year":"2022","journal-title":"Neurourol Urodyn."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jsxm.2022.07.003","article-title":"Effects of pelvic floor muscle training on sexual dysfunction, sexual satisfaction of partners, urinary symptoms, and pelvic floor muscle strength in women with overactive bladder: a randomized controlled study.","volume":"19","author":"Celenay","year":"2022","journal-title":"J Sex Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis.","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.08.002","article-title":"The differential risk of mortality among users of overactive bladder anticholinergic medications and \u03b23 agonists.","author":"Welk","year":"2022","journal-title":"Eur Urol Focus."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.22.04849-2","article-title":"Adverse events related to antimuscarinics and beta-3-agonist: \u201creal-life\u201d data from the Eudra-Vigilance database.","author":"De Nunzio","year":"2022","journal-title":"Minerva Urol Nephrol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6475014","article-title":"Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial.","volume":"2022","author":"Staskin","year":"2022","journal-title":"Int J Clin Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2019.07.010","article-title":"Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment.","volume":"76","author":"Gratzke","year":"2019","journal-title":"Eur Urol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5213\/inj.2040188.094","article-title":"Detrusor overactivity may be a prognostic factor for better response to combination therapy over monotherapy in male patients with benign prostatic enlargement and storage lower urinary tract symptoms.","volume":"25","author":"Sakalis","year":"2021","journal-title":"Int Neurourol J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II).","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2020.12.032","article-title":"Beyond antimuscarinics: a review of pharmacological and interventional options for overactive bladder management in men.","volume":"79","author":"De Nunzio","year":"2021","journal-title":"Eur Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mayocp.2019.11.024","article-title":"Evaluation and treatment of overactive bladder in women.","volume":"95","author":"Raju","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2700227","article-title":"Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines.","volume":"2022","author":"Al-Danakh","year":"2022","journal-title":"Parkinsons Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S0302-2838(21)00419-X","article-title":"Sacral neuromodulation with the InterStim\u2122 system for intractable lower urinary tract dysfunctions (SOUNDS): results of clinical effectiveness, quality of life, patient-reported outcomes and safety in a french multicenter observational study.","volume":"7","author":"Chartier-Kastler","year":"2021","journal-title":"Eur Urol Focus."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.04.006","article-title":"Sacral neuromodulation using a novel device with a six-contact-point electrode for the treatment of patients with refractory overactive bladder: a multicenter, randomized, single-blind, parallel-control clinical trial.","author":"Liao","year":"2022","journal-title":"Eur Urol Focus."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurom.2022.04.034","article-title":"Transcutaneous tibial nerve stimulation in the management of overactive bladder: a scoping review.","author":"Sayner","year":"2022","journal-title":"Neuromodulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo.","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12020128","article-title":"Comparing the efficacy of onabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation as third line treatment for the management of overactive bladder symptoms in adults: systematic review and network meta-analysis.","volume":"12","author":"Lo","year":"2020","journal-title":"Toxins."},{"key":"B23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/jrsm.1157","article-title":"Meta-analysis in Stata using gllamm.","volume":"6","author":"Bagos","year":"2015","journal-title":"Res Synth Methods."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00271","article-title":"How to conduct a bayesian network meta-analysis.","volume":"7","author":"Hu","year":"2020","journal-title":"Front Vet Sci."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211018537","article-title":"Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.","volume":"13","author":"Sheng","year":"2021","journal-title":"Ther Adv Med Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making."},{"key":"B28","author":"Dias","year":"2014","journal-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials."},{"key":"B29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder.","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ageing\/afu017","article-title":"The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.","volume":"43","author":"Wagg","year":"2014","journal-title":"Age Ageing."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1756287216672180","article-title":"Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.","volume":"9","author":"Eldred-Evans","year":"2017","journal-title":"Ther Adv Urol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.64","article-title":"Incontinence: onabotulinumtoxinA safer than abobotulinumtoxinA for OAB.","volume":"10","author":"Clyne","year":"2013","journal-title":"Nat Rev Urol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235961","article-title":"Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: a retrospective single-institution study.","volume":"15","author":"Kaaki","year":"2020","journal-title":"PLoS One."},{"key":"B35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17434440.2022.2032655","article-title":"Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.","volume":"19","author":"Tilborghs","year":"2022","journal-title":"Expert Rev Med Devices."},{"key":"B36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.euf.2019.11.018","article-title":"Sacral neuromodulation: mechanism of action.","volume":"6","author":"De Wachter","year":"2020","journal-title":"Eur Urol Focus."},{"key":"B37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.23736\/S2724-6051.19.03492-1","article-title":"Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation.","volume":"73","author":"Bianchi","year":"2021","journal-title":"Minerva Urol Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/nau.24254","article-title":"Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients.","volume":"39","author":"Te Dorsthorst","year":"2020","journal-title":"Neurourol Urodyn."},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/nau.22266","article-title":"Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.","volume":"32","author":"Peters","year":"2013","journal-title":"Neurourol Urodyn."},{"key":"B40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","article-title":"Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.","volume":"14","author":"Arlandis","year":"2011","journal-title":"Value Health."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.juro.2013.04.131","article-title":"Re: cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: M. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189: 210-216.","volume":"190","author":"Barnett","year":"2013","journal-title":"J Urol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.juro.2009.08.031","article-title":"Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.","volume":"182","author":"Siddiqui","year":"2009","journal-title":"J Urol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.euf.2018.05.004","article-title":"Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment?.","volume":"4","author":"Marcelissen","year":"2018","journal-title":"Eur Urol Focus."},{"key":"B44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/M15-0623","article-title":"Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.","volume":"163","author":"Bannuru","year":"2015","journal-title":"Ann Intern Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1014291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:53:31Z","timestamp":1666248811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1014291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":44,"alternative-id":["10.3389\/fmed.2022.1014291"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1014291","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1014291"}}